232 related articles for article (PubMed ID: 20065643)
1. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.
Reichert JM; Beck A; Iyer H
MAbs; 2009; 1(5):394-416. PubMed ID: 20065643
[TBL] [Abstract][Full Text] [Related]
2. Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany.
Reichert JM
MAbs; 2011; 3(3):223-40. PubMed ID: 21487235
[TBL] [Abstract][Full Text] [Related]
3. Typical pitfalls in applications for marketing authorization of biotechnological products in Europe.
Schneider CK; Schäffner-Dallmann G
Nat Rev Drug Discov; 2008 Nov; 7(11):893-9. PubMed ID: 18974748
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
Scott BJ; Klein AV; Wang J
J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
[TBL] [Abstract][Full Text] [Related]
5. Statistical assessment of biosimilar products.
Chow SC; Liu JP
J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
[TBL] [Abstract][Full Text] [Related]
6. Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014).
Cook G; France G; Holte Ø; Lorenti G; Tainsh D
PDA J Pharm Sci Technol; 2016; 70(2):163-76. PubMed ID: 26797977
[TBL] [Abstract][Full Text] [Related]
7. Relevant issues to biossimilars licensing.
Peres BS; Padilha G; Quental C
Rev Bras Epidemiol; 2012 Dec; 15(4):748-60. PubMed ID: 23515771
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.
Combe C; Tredree RL; Schellekens H
Pharmacotherapy; 2005 Jul; 25(7):954-62. PubMed ID: 16006274
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar medicines--new challenges for a new class of medicine.
Fox A
J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
[TBL] [Abstract][Full Text] [Related]
10. 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.
Beck A; Wurch T; Reichert JM
MAbs; 2011; 3(2):111-32. PubMed ID: 21441785
[TBL] [Abstract][Full Text] [Related]
11. Analytical aspects of biosimilarity issues of protein drugs.
Kálmán-Szekeres Z; Olajos M; Ganzler K
J Pharm Biomed Anal; 2012 Oct; 69():185-95. PubMed ID: 22633839
[TBL] [Abstract][Full Text] [Related]
12. [The regulatory framework for complementary and alternative medicines in Europe].
Knöss W; Stolte F; Reh K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
[TBL] [Abstract][Full Text] [Related]
13. A consistency approach for evaluation of biosimilar products.
Tsou HH; Chang WJ; Hwang WS; Lai YH
J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
[TBL] [Abstract][Full Text] [Related]
14. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
15. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
16. Overhauling oversight--European drug legislation.
Tsang L
Nat Biotechnol; 2005 Sep; 23(9):1050-3. PubMed ID: 16151389
[TBL] [Abstract][Full Text] [Related]
17. Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey.
Oner ZG; Michel SLJ; Polli JE
Ann N Y Acad Sci; 2017 Nov; 1407(1):26-38. PubMed ID: 29090833
[TBL] [Abstract][Full Text] [Related]
18. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
Moorkens E; Vulto AG; Huys I
MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
[TBL] [Abstract][Full Text] [Related]
19. Regulatory considerations in oncologic biosimilar drug development.
Macdonald JC; Hartman H; Jacobs IA
MAbs; 2015; 7(4):653-61. PubMed ID: 25961747
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union.
van Aerts LA; De Smet K; Reichmann G; van der Laan JW; Schneider CK
MAbs; 2014; 6(5):1155-62. PubMed ID: 25517301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
